Cargando…
Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands
Background and purpose — Tenosynovial giant cell tumors (TGCT) are rare, benign tumors, arising in synovial lining of joints, tendon sheaths, or bursae. 2 types are distinguished: localized, either digits or extremity, and diffuse lesions. Current TGCT incidence is based on 1 single US-county study...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694816/ https://www.ncbi.nlm.nih.gov/pubmed/28787222 http://dx.doi.org/10.1080/17453674.2017.1361126 |
_version_ | 1783280206079852544 |
---|---|
author | Mastboom, Monique J L Verspoor, Floortje G M Verschoor, Arjan J Uittenbogaard, Daniël Nemeth, Banne Mastboom, Walter J B Bovée, Judith V M G Dijkstra, P D Sander Schreuder, H W Bart Gelderblom, Hans Van de Sande, Michiel A J |
author_facet | Mastboom, Monique J L Verspoor, Floortje G M Verschoor, Arjan J Uittenbogaard, Daniël Nemeth, Banne Mastboom, Walter J B Bovée, Judith V M G Dijkstra, P D Sander Schreuder, H W Bart Gelderblom, Hans Van de Sande, Michiel A J |
author_sort | Mastboom, Monique J L |
collection | PubMed |
description | Background and purpose — Tenosynovial giant cell tumors (TGCT) are rare, benign tumors, arising in synovial lining of joints, tendon sheaths, or bursae. 2 types are distinguished: localized, either digits or extremity, and diffuse lesions. Current TGCT incidence is based on 1 single US-county study in 1980, with an incidence of 9 and 2 per million person-years in localized (including digits) and diffuse TGCT, respectively. We aim to determine nationwide and worldwide incidence rates (IR) in TGCT affecting digits, localized-extremity TGCT and diffuse-type TGCT. Material and methods — Over a 5-year period, the Dutch Pathology Registry (PALGA) identified 4,503 pathology reports on TGCT. Reports affecting digits were solely used for IR calculations. Reports affecting extremities were clinically evaluated. Dutch IRs were converted to world population IRs. Results — 2,815 (68%) digits, 933 (23%) localized-extremity and 390 (9%) diffuse-type TGCT were identified. Dutch IR in digits, localized-extremity, and diffuse-type TGCT was 34, 11 and 5 per million person-years, respectively. All 3 groups showed a female predilection and highest number of new cases in age category 40–59 years. The knee joint was most often affected: localized-extremity (46%) and diffuse-type (64%) TGCT, mostly treated with open resection: localized (65%) and diffuse (49%). Reoperation rate due to local recurrence for localized-extremity was 9%, and diffuse TGCT 23%. Interpretation — This first nationwide study and detailed analyses of IRs in TGCT estimated a worldwide IR in digits, localized-extremity and diffuse TGCT of 29, 10, and 4 per million person-years, respectively. Recurrence rate in diffuse type is 2.6 times higher, compared with localized extremity. TGCT is still considered a rare disease; however, it is more common than previously understood. |
format | Online Article Text |
id | pubmed-5694816 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-56948162017-11-27 Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands Mastboom, Monique J L Verspoor, Floortje G M Verschoor, Arjan J Uittenbogaard, Daniël Nemeth, Banne Mastboom, Walter J B Bovée, Judith V M G Dijkstra, P D Sander Schreuder, H W Bart Gelderblom, Hans Van de Sande, Michiel A J Acta Orthop Miscellaneous Background and purpose — Tenosynovial giant cell tumors (TGCT) are rare, benign tumors, arising in synovial lining of joints, tendon sheaths, or bursae. 2 types are distinguished: localized, either digits or extremity, and diffuse lesions. Current TGCT incidence is based on 1 single US-county study in 1980, with an incidence of 9 and 2 per million person-years in localized (including digits) and diffuse TGCT, respectively. We aim to determine nationwide and worldwide incidence rates (IR) in TGCT affecting digits, localized-extremity TGCT and diffuse-type TGCT. Material and methods — Over a 5-year period, the Dutch Pathology Registry (PALGA) identified 4,503 pathology reports on TGCT. Reports affecting digits were solely used for IR calculations. Reports affecting extremities were clinically evaluated. Dutch IRs were converted to world population IRs. Results — 2,815 (68%) digits, 933 (23%) localized-extremity and 390 (9%) diffuse-type TGCT were identified. Dutch IR in digits, localized-extremity, and diffuse-type TGCT was 34, 11 and 5 per million person-years, respectively. All 3 groups showed a female predilection and highest number of new cases in age category 40–59 years. The knee joint was most often affected: localized-extremity (46%) and diffuse-type (64%) TGCT, mostly treated with open resection: localized (65%) and diffuse (49%). Reoperation rate due to local recurrence for localized-extremity was 9%, and diffuse TGCT 23%. Interpretation — This first nationwide study and detailed analyses of IRs in TGCT estimated a worldwide IR in digits, localized-extremity and diffuse TGCT of 29, 10, and 4 per million person-years, respectively. Recurrence rate in diffuse type is 2.6 times higher, compared with localized extremity. TGCT is still considered a rare disease; however, it is more common than previously understood. Taylor & Francis 2017-11 2017-08-08 /pmc/articles/PMC5694816/ /pubmed/28787222 http://dx.doi.org/10.1080/17453674.2017.1361126 Text en © 2017 The Author(s). Published by Taylor & Francis on behalf of the Nordic Orthopedic Federation. https://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0) |
spellingShingle | Miscellaneous Mastboom, Monique J L Verspoor, Floortje G M Verschoor, Arjan J Uittenbogaard, Daniël Nemeth, Banne Mastboom, Walter J B Bovée, Judith V M G Dijkstra, P D Sander Schreuder, H W Bart Gelderblom, Hans Van de Sande, Michiel A J Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands |
title | Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands |
title_full | Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands |
title_fullStr | Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands |
title_full_unstemmed | Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands |
title_short | Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands |
title_sort | higher incidence rates than previously known in tenosynovial giant cell tumors: a nationwide study in the netherlands |
topic | Miscellaneous |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694816/ https://www.ncbi.nlm.nih.gov/pubmed/28787222 http://dx.doi.org/10.1080/17453674.2017.1361126 |
work_keys_str_mv | AT mastboommoniquejl higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands AT verspoorfloortjegm higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands AT verschoorarjanj higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands AT uittenbogaarddaniel higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands AT nemethbanne higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands AT mastboomwalterjb higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands AT boveejudithvmg higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands AT dijkstrapdsander higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands AT schreuderhwbart higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands AT gelderblomhans higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands AT vandesandemichielaj higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands AT higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands |